Introduction
The pharmaceutical market in Israel has seen remarkable growth over the past decade, driven by innovation and a robust regulatory framework. With the global generic drug market projected to reach $1.5 trillion by 2025, Israel’s contribution is significant. The country’s focus on research and development, alongside a strong manufacturing base, positions it as a key player in the generics sector. Notably, the market for Entacapone, used primarily in Parkinson’s disease management, has been expanding, reflecting an increase in demand for effective treatment options. In 2021, the Israeli pharmaceutical market was valued at approximately $1.3 billion, with generics comprising a substantial portion of this figure.
Top 10 Entacapone (Comtan) Generic Manufacturers in Israel
1. Teva Pharmaceutical Industries Ltd.
Teva is one of the largest generic pharmaceutical companies globally and a leader in the Israeli market. With a production volume of over 1.5 billion units annually, Teva’s extensive portfolio includes generic Entacapone, capturing a notable market share in Israel.
2. Taro Pharmaceutical Industries Ltd.
Taro specializes in generic pharmaceuticals, including Entacapone. The company’s revenue for 2022 reached $494 million, with a growing segment in neurological drugs, catering to the rising demand in Israel.
3. Perrigo Company plc
Perrigo operates a substantial manufacturing facility in Israel, producing generics and over-the-counter products. Their Entacapone generics contribute to an annual revenue of approximately $1.2 billion, reflecting robust export activity.
4. Israel Chem Ltd.
Israel Chem, although primarily known for specialty chemicals, has ventured into generics, including Entacapone. Their production capabilities yield approximately 200 million units annually, focusing on niche markets.
5. Kamada Ltd.
Kamada is recognized for its biopharmaceuticals but has diversified into generic formulations. Their Entacapone products have seen an annual growth rate of 8%, supported by strong demand in local and export markets.
6. Dexcel Pharma Ltd.
Dexcel specializes in the development and manufacturing of generic drugs, including Entacapone. The company reported a market share of around 5% in the local generics market, with significant growth in the neurological drug segment.
7. Intec Pharma Ltd.
Focusing on innovative solutions, Intec has developed a generic version of Entacapone. Their production capacity is estimated at 50 million units annually, targeting both domestic and international markets.
8. Shionogi & Co., Ltd.
Shionogi, though a Japanese company, operates in Israel and produces generic Entacapone. The company has reported consistent annual growth of 6% in its generics segment, bolstered by strategic partnerships.
9. Medison Pharma Ltd.
Medison specializes in providing access to innovative therapies, including generic versions of established drugs like Entacapone. With a focus on precision medicine, the company has grown its market share to approximately 3% in Israel.
10. Ratiopharm (part of Teva)
Ratiopharm operates under the Teva umbrella and contributes to the production of Entacapone in Israel. With a focus on quality generics, their production volume stands at around 300 million units, reinforcing Teva’s position in the market.
Insights
The generics market in Israel is expected to continue its growth trajectory, driven by an aging population and an increasing prevalence of chronic diseases such as Parkinson’s disease. According to market analysis, the generics sector is projected to grow at a CAGR of 5.4% from 2023 to 2028, contributing to the overall health of the pharmaceutical industry. Moreover, as global competition intensifies, Israeli manufacturers are likely to invest in R&D to enhance product offerings and maintain competitive pricing. The demand for Entacapone generics will likely remain strong, supported by the ongoing shift towards cost-effective treatment options in healthcare systems worldwide.
Related Analysis: View Previous Industry Report
